Nutriband Inc. (NASDAQ:NTRB) Short Interest Update

Nutriband Inc. (NASDAQ:NTRB) saw a significant increase in short interest during the month of February. As of February 15th, there was short interest totalling 361,000 shares, an increase of 37.7% from the January 31st total of 262,100 shares. Based on an average daily volume of 202,200 shares, the days-to-cover ratio is presently 1.8 days. Currently, 7.1% of the shares of the company are short sold.

Nutriband Stock Performance

Shares of NTRB stock traded up $0.08 during mid-day trading on Tuesday, hitting $6.96. 43,701 shares of the stock were exchanged, compared to its average volume of 82,871. The stock’s fifty day simple moving average is $6.22 and its two-hundred day simple moving average is $5.62. The stock has a market capitalization of $77.30 million, a price-to-earnings ratio of -9.80 and a beta of 1.08. Nutriband has a 12-month low of $2.22 and a 12-month high of $11.78. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.83 and a current ratio of 4.96.

Nutriband (NASDAQ:NTRB) last issued its quarterly earnings data on Tuesday, December 3rd. The company reported ($0.12) earnings per share (EPS) for the quarter. Nutriband had a negative return on equity of 54.49% and a negative net margin of 338.51%. On average, analysts forecast that Nutriband will post -0.6 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Noble Financial assumed coverage on Nutriband in a report on Wednesday, January 22nd. They set an “outperform” rating and a $13.00 price objective on the stock.

Hedge Funds Weigh In On Nutriband

A hedge fund recently bought a new stake in Nutriband stock. Haven Private LLC purchased a new position in shares of Nutriband Inc. (NASDAQ:NTRB) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 11,561 shares of the company’s stock, valued at approximately $54,000. Haven Private LLC owned about 0.10% of Nutriband as of its most recent SEC filing. Institutional investors and hedge funds own 19.70% of the company’s stock.

About Nutriband

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.